- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/28 - Radicals substituted by singly-bound oxygen or sulfur atoms
Patent holdings for IPC class C07D 213/28
Total number of patents in this class: 21
10-year publication summary
|
2
|
0
|
2
|
0
|
0
|
3
|
0
|
1
|
0
|
0
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| sanofi-aventis | 327 |
4 |
| Abbvie Inc. | 1840 |
2 |
| Battelle Memorial Institute | 2596 |
2 |
| Novartis AG | 10341 |
1 |
| Centre National de La Recherche Scientifique | 10895 |
1 |
| Dow AgroSciences LLC | 1195 |
1 |
| Givaudan SA | 1959 |
1 |
| GW Research Limited | 146 |
1 |
| Icahn School of Medicine at Mount Sinai | 1007 |
1 |
| Medical Research Council | 137 |
1 |
| Universite Rene Descartes (Paris V) | 11 |
1 |
| IFM Therapeutics, Inc | 1 |
1 |
| Vivace Therapeutics, Inc. | 31 |
1 |
| Sanofi | 4249 |
1 |
| Xyzagen, Inc. | 16 |
1 |
| Pharma IP Limited Liability Intermediary Corporations | 2 |
1 |
| Other owners | 0 |